First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma

被引：0
|
作者：
Garralda, Elena
Oberoi, Arjun
de Velasco, Guillermo
Victoria, Ivan
Pesantez, David
Eguren Santamaria, Inaki
Moreno, Victor
Boni, Valentina
Cervantes, Andres
Gambardella, Valentina
Ciuleanu, Tudor-Eliade
Bergamino Sirven, Milana
Rodriguez-Abreu, Delvys
Alonso, Guzman
Minea Gales, Laurentia
Jones, Daniel
Patki, Abhay
Ataman, Ozlem
Melero Bermejo, Ignacio
机构：
[1] Vall dHebron Univ Hosp HUVH, Barcelona, Spain
[2] Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[3] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] Hosp Clin Barcelona, Barcelona, Spain
[6] Clin Univ Navarra, Pamplona, Spain
[7] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[8] Univ Hosp Quiron Salud, NEXT Oncol, Madrid, Spain
[9] Hosp Clin Univ Valencia, Valencia, Spain
[10] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania
[11] Univ Med & Pharm Iuliu Hatieganu, Cluj Napoca, Romania
[12] H U Germans Trias & Pujol, ICO Badalona, Barcelona, Spain
[13] Complejo Hosp Univ Insular Materno Infant, Las Palmas Gran Canaria, Spain
[14] Hosp Quironsalud, NEXT Oncol, Barcelona, Spain
[15] Carol Davila Univ Med & Pharm, Bucharest, Romania
[16] InvoX Pharma Ltd, London, England
[17] Clin Univ Navarra, Pamplona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2505
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A first-in-human phase I study of FS222, a CD137/PD-L1 tetravalent bispecific antibody, in patients with advanced malignancies
    Garralda, E.
    Melero, I.
    de Velasco, G.
    Moreno, V.
    Oberoi, H. K.
    Shepherd, C.
    Jones, D.
    Lakins, M. A.
    Hurley, P.
    Khambhatwala, S.
    Long, D.
    Kayitalire, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1454 - S1454
  • [2] FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
    Lakins, Matthew A.
    Koers, Alexander
    Giambalvo, Raffaella
    Munoz-Olaya, Jose
    Hughes, Robert
    Goodman, Emma
    Marshall, Sylwia
    Wollerton, Francisca
    Batey, Sarah
    Gliddon, Daniel
    Tuna, Mihriban
    Brewis, Neil
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 4154 - 4167
  • [3] FS222, a tetravalent bispecific antibody targeting CD137 and PD-L1, is designed for optimal CD137 interactions resulting in potent T cell activation without toxicity.
    Lakins, Matthew A.
    Munoz-Olaya, Jose
    Veyssier, Christel
    Jones, Daniel
    Goodman, Emma
    Kaka, Quincy
    Ofoedu, Jennifer
    Hughes, Robert
    Gliddon, Daniel
    Morrow, Michelle
    Brewis, Neil
    CANCER RESEARCH, 2021, 81 (13)
  • [4] A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
    Yap, Timothy A.
    LoRusso, Patricia M.
    Wong, Deborah J.
    Hu-Lieskovan, Siwen
    Papadopoulos, Kyriakos P.
    Holz, Josefin-Beate
    Grabowska, Urszula
    Gradinaru, Cristian
    Leung, Kin-Mei
    Marshall, Sylwia
    Reader, Claire S.
    Russell, Roslin
    Sainson, Richard C. A.
    Seal, Claire J.
    Shepherd, Christopher J.
    Germaschewski, Fiona
    Gliddon, Daniel
    Stern, Omer
    Young, Lesley
    Brewis, Neil
    Kayitalire, Louis
    Morrow, Michelle
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 888 - 898
  • [5] Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors
    Carneiro, Benedito A.
    Safran, Howard
    Beck, J. Thaddeus Thaddeus
    Hamid, Omid
    Spira, Alexander I.
    Savvides, Panos
    Gutierrez, Martin
    Zhao, Yujie
    Abbruzzese, James L.
    Ward, Jeffrey P.
    Weroha, Saravut John
    Harris, Loleta D.
    Kent, Sean
    Pierceall, William
    Skoura, Athanasia
    Zheng, Jenny
    Kern, Kenneth Alan
    Thomas, Jacob Stephen
    Santana-Davila, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.
    Yap, Timothy A.
    Papadopoulos, Kyriakos P.
    LoRusso, Patricia
    Wong, Deborah J. L.
    Hu-Lieskovan, Siwen
    Holz, Josefin-Beate
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] A FIRST-IN-HUMAN STUDY OF FS118, A TETRAVALENT BISPECIFIC ANTIBODY TARGETING LAG-3 AND PD-L1, IN PATIENTS WITH ADVANCED CANCER AND RESISTANCE TO PD-(L)1 THERAPY
    Yap, Timothy
    Wong, Deborah
    Hu-Lieskovan, Siwen
    Papadopoulos, Kyriakos
    Morrow, Michelle
    Grabowska, Urszula
    Gliddon, Daniel
    Holz, Josefin-Beate
    LoRusso, Patricia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A240 - A240
  • [8] Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors
    Prenen, H.
    Kyi, C.
    Van Lancker, G.
    Patel, S. P.
    Mittag, D.
    Weaver, A.
    Bol, K.
    Stalbovskaya, V.
    Pulini, J.
    Zhou, G.
    Dong, Z.
    Asatiani, E.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1436 - S1436
  • [9] A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
    Huang, Po-Lin
    Kan, Hung-Tsai
    Hsu, Ching-Hsuan
    Hsieh, Hsin-Ta
    Cheng, Wan-Chien
    Huang, Ren-Yeong
    You, Jhong-Jhe
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [10] Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
    Janice M. Mehnert
    Andrea Varga
    Marcia S. Brose
    Rahul R. Aggarwal
    Chia-Chi Lin
    Amy Prawira
    Filippo de Braud
    Kenji Tamura
    Toshihiko Doi
    Sarina A. Piha-Paul
    Jill Gilbert
    Sanatan Saraf
    Pradeep Thanigaimani
    Jonathan D. Cheng
    Bhumsuk Keam
    BMC Cancer, 19
12345